Disruption or dysfunction of organelles (including mitochondria) that liberate ROS during glucose and fatty acid metabolism, via SGLT-2 inhibition, also significantly alleviates AF burden and tachyarrhythmias in these conditions [31]. The gene discussed is SLC5A2; the disease is atrial fibrillation.